Background and Purpose-Autoimmune responses can occur when antigens from the central nervous system are presented to lymphocytes in the periphery or central nervous system in several neurological diseases. However, whether autoimmune responses emerge after brain ischemia and their impact on clinical outcomes remains controversial. We hypothesized that brain ischemia facilitates the genesis of autoimmunity and aggravates ischemic brain injury. Methods-Using a mouse strain that harbors a transgenic T-cell receptor to a central nervous system antigen, MOG (myelin oligodendrocyte glycoprotein) epitope (2D2), we determined the anatomic location and involvement of antigenpresenting cells in the development of T-cell reactivity after brain ischemia and how T-cell reactivity impacts stroke outcome. Transient middle cerebral artery occlusion and photothrombotic stroke models were used in this study. We also quantified the presence and status of T cells from brain slices of ischemic patients. 
S
troke is a devastating disorder that causes significant morbidity and mortality worldwide. Little progress has been made in finding new remedies for patients beyond the therapeutic window of tPA (tissue-type plasminogen activator). 1, 2 Autoimmune responses can occur when lymphocytes encounter brain antigens in the periphery or within the brain. [3] [4] [5] Several studies during the past decade have attempted to determine how autoimmune responses to brain antigens can emerge in patients with stroke and in rodents after middle cerebral artery occlusion (MCAO). [4] [5] [6] For example, both antibodies and circulating T cells can become sensitized to brain antigens, such as MBP (myelin basic protein) and related peptides, [7] [8] [9] whereas other studies failed to demonstrate this. 3, 5 Therefore, development of autoimmunity to brain antigens in stroke remains debated.
Autoimmune responses are highly influenced by CD4 + T cells. 10, 11 In autoimmune diseases, the anatomic locations for activation of autoreactive T cells may include peripheral lymphoid organs, such as the spleen or cervical lymph nodes, as well as the central nervous system (CNS). Yet the timing, anatomic location, and antigen-presenting cells (APCs) possibly involved in the trigger of autoimmunity in stroke remain ill defined. Similarly, it is debated whether possible development of autoimmune responses can impact stroke outcomes. Although it has been reported that the adoptive transfer of lymphocytes against myelin antigen exacerbates stroke lesions
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June 2018 play a detrimental or protective role on stroke outcomes. Here, we investigated the possibility that T-cell responses diversify after brain ischemia and that the expanded CNS antigen-specific T cells could promote brain injury.
Materials and Methods
This article adheres to the American Heart Association Journals implementation of the Transparency and Openness Promotion Guidelines. Details of materials and experimental procedures are available in the online-only Data Supplement. The data that support the findings of this study are available from the corresponding author on reasonable request. 
Human Brain Sections

Mice
We purchased male C57BL/6 (B6, H-2 b ) and Rag2 -/-mice from Taconic (Santa Maria, CA). Ovalbumin (OVA) and 2D2 transgenic mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Details of mice used in this study are given in Methods in the onlineonly Data Supplement.
MCAO and Photothrombosis Procedure, Neurological Assessment, Neuroimaging, and Immunostaining
Adult male 10-to 12-week-old mice were subjected to 60 minutes of focal cerebral ischemia produced by transient intraluminal occlusion of the middle cerebral artery using a filament as described previously. [15] [16] [17] Details of the MCAO and photothrombotic stroke procedures, neurological assessment, magnetic resonance imaging scan, and immunostaining are provided in Methods in the online-only Data Supplement.
Drug Administration
PLX3397 (Selleck Chemicals, Houston, Texas) was prepared and given as we described previously. Details are provided in Methods in the online-only Data Supplement. ) were isolated from pooled splenocytes of WT (wild type), OVA, or 2D2 mice. Cell isolation, cell labeling, cell passive transfer, CFSE (carboxyfluorescein succinimidyl ester) assay, tetramer staining, flow cytometry, and ELISA were performed as described previously. [15] [16] [17] Details are given in Methods in the online-only Data Supplement.
Cell Isolation and
Statistical Analyses
Details of statistical analyses are given in Methods in the online-only Data Supplement. Significance was set at P<0.05. Data are shown as means±SEM.
Results
Expansion of T-Cell Reactivity to Neuroantigens Occurs in the Brain After Ischemia
Because of the heterogeneity/diversity in T-cell receptor (TCR) expression and the inherent technical limitations in measuring antigen-specific T-cell response in vivo, limited information is currently available on the dynamics of T-cell responses to neuroantigens after brain ischemia. Because MOG (myelin oligodendrocyte glycoprotein) is a neuroantigen that can be rapidly released into the periphery after brain ischemia, 13, 18 we used transgenic mice that harbor a CD4 + MOG 35-55 -specific T-cell clone (2D2). In these mice, the majority of CD4 + T cells express a Vα3.2 and Vβ11 TCR, and a large proportion of these mice spontaneously develop optic neuritis, suggesting preexisting CNS infiltration of autoreactive T cells and baseline CNS inflammation in these animals.
To measure the anatomic location and timing of T-cell changes after stroke, we adoptively transferred naive-like 2D2 CD4 + T cells (CD4 + CD44 low CD62L high Vα3.2 + Vβ11 + ) presorted from spleens of naive 2D2 mice that did not have any CNS inflammation ( Figure 1A 
Antigen-Specific T Cells Are Activated Locally in the Brain After Ischemia
Little is known about the anatomic location where T cells are activated in response to brain antigens. To define the location of T-cell activation and the timing of the autoreactive T-cell response after cerebral ischemia, we transferred CFSE-labeled 
2D2 T Cells Are Activated by Local APCs in the Brain After Cerebral Ischemia
Although CD4 + T cells are activated by MHC II presentation of epitopes by APCs, recent data also suggest alternative pathways that may not depend on MHC II. 14, 19 To determine whether MHC II/TCR interaction is required for brain ischemia-induced expansion of 2D2 CD4 + T cells to MOG epitopes, we used MHC II knockout mice (H2-Ab1 
Supplement
). These data demonstrate a strong capacity of microglia to present brain antigen peptides to T cells.
We also depleted microglia using PLX3397-an inhibitor of colony stimulating factor 1 receptor, which specifically depletes microglia. 21 We found that reduction of microglia abolished the increase of MOG 91-108 -or MOG 103-125 -specific 2D2 T cells ( Figure VIII in the online-only Data Supplement). These data imply that brain-resident microglia are key APCs for the expansion of 2D2 T-cell reactivity to brain antigens in the ischemic brain.
Diversified T-Cell Responses Exacerbate Ischemic Brain Injury
To evaluate the impact of brain ischemia-induced diversification of T-cell response on stroke outcomes, we used 2D2 CD4 + T cells from spleens of sham 2D2 mice and antigen-experienced 2D2 CD4 + T cells from spleens of 2D2 mice at day 7 after MCAO or photothrombosis. We transferred WT, OVAspecific, 2D2, or antigen-experienced 2D2 CD4 + T cells into Rag2 −/− mice before MCAO or photothrombosis ( Figure 4A ). More severe neurodeficits and significantly larger infarct volumes were seen in Rag2 −/− mice receiving antigen-experienced 2D2 CD4 + T cells as compared with WT mice, OVAspecific, or 2D2 CD4 + T cells from naive 2D2 mice, starting at day 4 after MCAO ( Figure 4B ) or at day 7 after photothrombotic stroke ( Figure 4C ). Increased neurodeficits and brain infarction volumes persisted at least until day 7 after MCAO ( Figure 4B ) or photothrombotic stroke ( Figure 4C ). Thus, brain ischemia-induced diversification of T-cell responses has a detrimental impact on ischemic brain injury. Figure 5C ), suggesting that antigen-experienced T cells exacerbate brain inflammation after cerebral ischemia.
These results imply that CD4 + T cells enter the brain and become activated after ischemia, where multiple brain antigens presented by local APCs diversify the T-cell responses that exacerbate brain infarction.
Presence of Neuroantigen-Specific T Cells in the Brain of Patients With Stroke
Brain slices from patients with acute middle cerebral artery ischemic stroke showed that CD4 + T cells infiltrated the infarct and peri-infarct areas. Some of these cells resided in close vicinity to ischemic neurons ( Figure XI 
Discussion
In this study, we precisely tracked the myelin-reactive T cells with tetramers and revealed that the antigen spectrum was expanded with the progression of ischemia-induced brain injury. To our knowledge, this study provides the first definitive evidence on the activation of CD4 + T cells, which subsequently acquire new reactivity within the brain.
The finding of the 2D2 T-cell specificities to MOG 91-108 and MOG suggests the expansion of T-cell reactivity against new brain antigen epitopes after stroke. This finding is supported by a previous study showing that T cells bearing the same Vα and Vβ genes can have different antigen specificity. 22 However, one might argue that new specificities could derive from carryover clones from the 2D2 donors or derive from MOG 35-55 -specific clones with cross-reactivity to the other 2 MOG peptides. Yet, MOG 35-55 -specific T cells isolated from naive 2D2 mice only had minimal reaction to MOG 91-108 and MOG , suggesting that MOG 35-55 -specific 2D2 T cells were specific, as also supported by the diversity of Vβ expression that supports the expansion of T-cell response in the poststroke environment. One recent study showed that stroke induced a secondary, dynamic autoimmune response to neuronal antigens, maintained through 10 days in both lymph nodes and spleen. 9 In line with those findings, our results suggest that the expansion of T-cell response could occur both in the periphery and CNS after ischemia. However, the activation and proliferation of naive-like 2D2 T cells were more prominent in the brain than in peripheral lymphoid organs, suggesting that the expansion of T cells could be initiated in the brain, possibly because of the strokeinduced environment. In support of this, another report suggested that the expansion of T-cell clones may occur first in the ischemic brain and subsequently in secondary lymphoid organs. 23 Thus, activation of T cells would occur predominantly in the CNS after stroke.
The findings of 2D2 T cells reactive to other MOG epitopes in the ischemic brain and its dependence on MHC II implicate antigen presentation. In the context of stroke, the CNS harbors both peripheral APCs homing into the ischemic brain and CNS-resident APCs. Our findings of higher numbers of MHC II-expressing microglia-like cells colocalizing with MOG peptide, together with their stronger capacity to present endogenous MOG, suggest a major role of microglia in the expansion of 2D2 T cells. Indeed, depletion of microglia ablated occurrence of new reactivity to additional MOG epitopes after stroke. Past studies reported the expression of MHC II on microglia on their activation and myelin debris phagocytosed by microglia in neuroinflammatory conditions. [24] [25] [26] More recent findings suggest that resident microglia are the first responders to brain ischemia and that phagocytosis of neural debris by microglia takes place in the early stages of stroke, before the arrival of infiltrating peripheral macrophages. 26, 27 Of note, microglia possess multiple functions, including antigen presentation and production of inflammatory factors, which enable microglia to interact with several cell types other than T cells. These diverse features suggest a profound role of microglia in brain injury depending on the settings of animal models and disease conditions. Some have suggested that myelin-reactive lymphocytes are detrimental in rodent stroke models, 13 and clinical studies have linked autoreactive T-cell responses to worsened outcomes in patients with stroke. 28 Our study suggests a series of events in which antigen presentation promotes T-cell expansion that fuels focal inflammation during the evolution of brain infarction and neurodeficit. This raises the possibility that preexisting or newly emerged brain antigen-specific T cells could favor brain injury in patients with first-ever or recurrent stroke attacks, implying possible therapeutic blockade of the recruitment and activation of T cells to attenuate ischemic brain injury. 
